Susan Hill is a Venture Partner at SV and CEO of Mestag Therapeutics, a company founded and seed funded by SV in 2020. She joined the SV Venture Partner Program in September 2020.
Susan has 20 years’ experience in biotech, operating in UK, Europe and US based companies. Prior to joining SV and Mestag, Susan served as Chief Business Officer of Gyroscope Therapeutics, a UK based company developing genetically defined therapies for ocular diseases such as age-related macular degeneration, focusing on the company’s $62m Series B round, business development and the integration of the Orbit Biomedical business, providing Gyroscope with unique delivery technology and its US base. Susan was the founding Chief Executive Officer of Orbit Biomedical (Philadelphia, US), securing a $12m Series A to commercialize technology acquired from Janssen.
Previously, Susan served as Chief Business Officer of Freeline Therapeutics, a UK based liver-directed gene therapy company (2020 IPO: FRLN). Susan has also served in the global Business & Corporate Development team at Alexion (ALXN; Lausanne, Switzerand) focusing on rare and ultra-rare diseases. During an 8-year tenure at Merck Serono (MRK; Geneva, Switzerland) Susan served in a series of Corporate & Business Development and Portfolio Management roles across neurodegenerative disease, autoimmune disease, neurodegenerative disease and oncology. Susan began her career in strategy consulting/M&A, followed by a 3-year tenure leading biotech seed investments.
MA (Natural Sciences, Christ’s College, Cambridge); PhD from the University of Cambridge in mitochondrial genetics; previous Fellow of the Securities Institute.